A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

December 12, 2025

Study Completion Date

December 9, 2026

Conditions

Gastric Type Adenocarcinoma (GAS) With STK11 Mutation

Interventions

DRUG

WX390

WX390 tablet, 0.9 mg once a day

DRUG

Toripalimab

240 mg, Day 1, every 3 weeks

Trial Locations (1)

RECRUITING

The Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital), Shanghai

All Listed Sponsors

lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY